These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27156864)

  • 21.
    Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
    JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.
    Vinjamuri S; Gilbert TM; Banks M; McKane G; Maltby P; Poston G; Weissman H; Palmer DH; Vora J; Pritchard DM; Cuthbertson DJ
    Br J Cancer; 2013 Apr; 108(7):1440-8. PubMed ID: 23492685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Utility of Total
    Tirosh A; Papadakis GZ; Millo C; Hammoud D; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
    Gastroenterology; 2018 Mar; 154(4):998-1008.e1. PubMed ID: 29155309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):8-9. PubMed ID: 27168104
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate.
    van Vliet EI; Krenning EP; Teunissen JJ; Bergsma H; Kam BL; Kwekkeboom DJ
    J Nucl Med; 2013 Oct; 54(10):1689-96. PubMed ID: 24084705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
    Sowa-Staszczak A; Pach D; Kunikowska J; Krolicki L; Stefanska A; Tomaszuk M; Buziak-Bereza M; Mikolajczak R; Matyja M; Gilis-Januszewska A; Jabrocka-Hybel A; Trofimiuk M; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2011; 62(5):392-400. PubMed ID: 22069099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
    Boucher JE; Sommers R
    Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of
    Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM
    Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716
    [No Abstract]   [Full Text] [Related]  

  • 29. Lutetium oxodotreotide (
    Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
    BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Valkema R; Pauwels S; Kvols LK; Barone R; Jamar F; Bakker WH; Kwekkeboom DJ; Bouterfa H; Krenning EP
    Semin Nucl Med; 2006 Apr; 36(2):147-56. PubMed ID: 16517236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.
    van Vliet EI; van Eijck CH; de Krijger RR; Nieveen van Dijkum EJ; Teunissen JJ; Kam BL; de Herder WW; Feelders RA; Bonsing BA; Brabander T; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2015 Nov; 56(11):1647-53. PubMed ID: 26272813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP
    Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
    Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
    Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.
    Brogsitter C; Zöphel K; Folprecht G; Eisenhofer G; Kotzerke J
    Nuklearmedizin; 2017 Jun; 56(3):N19-N21. PubMed ID: 28358166
    [No Abstract]   [Full Text] [Related]  

  • 35. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
    Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
    AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
    Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
    Ryan P; Phan AT; Adelman DT; Iwasaki M
    Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database.
    Fisher MD; Pulgar S; Kulke MH; Mirakhur B; Miller PJ; Walker MS; Schwartzberg LS
    J Gastrointest Cancer; 2019 Dec; 50(4):816-823. PubMed ID: 30121904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.